Fischer Medical Ventures Limited appointed David Yeow as an additional independent director effective September 3, 2026. The company also announced September 22, 2026, as the record date for its 33rd Annual General Meeting and dividend entitlement.

The Board of Directors approved these governance updates in a meeting held on September 3, 2026. The appointment was made pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The record date intimation was issued under Regulation 42 of the same regulations.

Director Appointment Details

Mr. Yeow joins the board for a first term of five consecutive years, subject to shareholder approval. He is not liable to retire by rotation. The Singapore-based engineer brings over three decades of experience in manufacturing, quality systems, and global supply chain management.

He holds a Diplôme d'Ingénieur in Electronic Engineering from the École Nationale Supérieure d'Électronique et de Radioélectricité de Bordeaux and is a GE-certified Six Sigma Blackbelt. Previously, he held senior leadership roles at GE Plastics, Lanxess, and NTUitive. He currently serves as Principal at Hunniwell Lake Ventures, a medical device venture capital firm.

Audit Committee Reconstitution

Following the new appointment, the Board reconstituted the Audit Committee. The committee now comprises seven members, including four independent directors, one executive director, and one whole-time director.

AGM Scheduling and Record Dates

The company will hold its 33rd Annual General Meeting on Tuesday, September 29, 2026, at 11:00 am through video conferencing or other audio-visual means. M/s Nuren Lodaya & Associates Practising Company Secretary has been appointed as the scrutinizer for the e-voting process.

The Register of Members and Share Transfer Books will remain closed from September 23, 2026, to September 29, 2026, inclusive. This closure facilitates the AGM proceedings.

Tuesday, September 22, 2026, is the cut-off date for determining voting rights for e-voting on resolutions listed in the AGM notice and for dividend entitlement. The cut-off date for determining shareholders entitled to receive the dispatch of the AGM notice was September 4, 2026.

Fischer Medical Ventures has entered the advanced diagnostic imaging segment through its wholly owned subsidiary, Time Medical International Ventures (India) Private Ltd. The launch of the CLARION 64/128-Slice AI-Driven CT System at the India Health Expo 2026 marks a strategic expansion into high-performance medical hardware.

The event was formally inaugurated by Dr. Sunil K. Khetrapal, Deputy Director General of the Association of Healthcare Providers India (AHPI). The presence of senior healthcare administrators signals industry validation for the platform’s focus on intelligent clinical workflows and sustainable healthcare delivery.

Product Specifications

The CLARION platform integrates high-performance imaging hardware with artificial intelligence to support diagnostic precision and operational efficiency. Key technical features include:

Clinical Configurations

The system is available in scalable configurations tailored to specific clinical requirements:

• 64-Slice Configuration: Features a 91 cm bore, suitable for vascular imaging and intraoperative applications.
• 128-Slice Configuration: Supports advanced procedures requiring higher temporal resolution, including cardiac, neurological, and thoracic imaging.

Interventional Capabilities

Beyond conventional diagnostics, the CLARION platform extends into interventional and surgical environments. The Big Bore CT-on-Rail configuration enables mobility between clinical scenarios and supports hybrid operating room integration. Advanced capabilities such as 4D CT phased acquisition assist in respiratory monitoring and tumor targeting during radiotherapy by reducing motion-related artifacts.

Strategic Context

Time Medical International Ventures specializes in the design and manufacture of high-performance MRI systems. The introduction of the CLARION CT system reinforces the group’s commitment to building a comprehensive medical imaging ecosystem that combines engineering innovation with AI-driven workflows.